Body Vision Medical, an AI-driven intraoperative CT imaging firm, and Ann Arbor’s Xoran Technologies, have announced the successful validation of Body Vision’s LungVision system with Xoran’s TRON system.
The LungVision system uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans. This empowers bronchoscopists to biopsy from smaller, more difficult-to-access lung lesions at an earlier stage, thus maximizing the likelihood of an early diagnosis for lung cancer patients and improving odds for survival.
TRON is a truly mobile, full-body fluoroscopy, CT X-ray system specifically designed to provide safe, ultra-high-resolution, low dose imaging directly in point-of-care settings such as the operating room, surgery center, and critical care units, thereby avoiding risky patient transport to radiology for CT imaging and enabling minimally invasive procedures (MIS).
“Body Vision’s approach with LungVision is to ensure that it works with existing equipment so that we empower health care providers to better serve a growing population of lung patients without ballooning overall operating costs,” says David Webster, CEO of Body Vision Medical.
“While our rapidly growing installed base is real-world evidence that our technology integrates seamlessly with any 2D/3D X-ray imaging system, for customers seeking added assurance, this formal validation of Xoran TRON for use with LungVision is one of several steps we are proactively taking to ensure consistency in system performance regardless of setup.”
Misha Rakic, CEO of Xoran Technologies, adds, “With MIS, workflow is everything, and Xoran is committed to point-of-care solutions that reduce OR time and improve outcomes. Pairing the LungVision AI-powered advanced imaging system with TRON’s lower dose fluoroscopy and true low-dose 3D CT capability, clinicians get better image resolution than previously available — in a compact, affordable device. This workflow enables unparalleled accuracy in intraoperative guidance for bronchoscopic biopsies of peripheral lung lesions while reducing procedure times.”